Institution Directory

Clinical trials at Cleveland Clinic

Sites in Cleveland, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 1:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1313

Shown on this page

Current sort

Stored official records

Conditions: Tricuspid Regurgitation
Interventions: Transcatheter Tricuspid Valve Replacement; Device
Lead sponsor: Trisol Medical; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 7
States / cities: Los Angeles, California • Atlanta, Georgia • New York, New York + 4 more

Conditions: Kidney Transplant Rejection
Interventions: Not listed
Lead sponsor: Verici Dx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 9
States / cities: Chicago, Illinois • Evanston, Illinois • Baltimore, Maryland + 6 more

Conditions: Cell-free DNA, Kidney Transplant Rejection
Interventions: donor-derived cell-free DNA test; Diagnostic Test
Lead sponsor: Insight Molecular Diagnostics; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 8
States / cities: Los Angeles, California • Jacksonville, Florida • Tampa, Florida + 5 more

Conditions: Acute Kidney Injury
Interventions: ProNephro AKI (NGAL); Diagnostic Test
Lead sponsor: BioPorto Diagnostics; Industry
Eligibility: 22 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 12
States / cities: Birmingham, Alabama • Sacramento, California • New Haven, Connecticut + 9 more

Conditions: Anogenital Cancers, Cervical Cancer, HPV - Anogenital Human Papilloma Virus Infection, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Malignancy, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, Head and Neck Cancer, Melanoma, Non-small Cell Carcinoma, Ovarian Cancer
Interventions: TSC-200-A0201, TSC-200-A0201 + TSC-201-B0702, TSC-200-A0201 + TSC-202-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-200-A0201 + TSC-204-A0101, TSC-201-B0702, TSC-201-B0702 + TSC-202-A0201, TSC-202-A0201, TSC-203-A0201, TSC-203-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-202-A0201, TSC-203-A0201 + TSC-204-A0101, TSC-204-A0101, TSC-204-A0101 + TSC-202-A0201, TSC-204-A0201, TSC-204-A0201 + TSC-200-A0201, TSC-204-A0201 + TSC-201-B0702, TSC-204-A0201 + TSC-202-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-204-C0702, TSC-204-C0702, TSC-204-C0702 + TSC-200-A0201, TSC-204-C0702 + TSC-201-B0702, TSC-204-C0702 + TSC-202-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-204-C0702 + TSC-204-A0101; Biological
Lead sponsor: TScan Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 21
States / cities: Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more

Conditions: Cervical Cancer, HPV16 Related Cancers, Head and Neck Cancer, NUT Carcinoma, Non Small Cell Lung Cancer, Sarcoma, Uveal Melanoma
Interventions: Tumor and HLA Profiling; Diagnostic Test
Lead sponsor: TScan Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 21
States / cities: Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more

Conditions: Crohns Disease
Interventions: Not listed
Lead sponsor: Alimentiv Inc.; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Rochester, Minnesota • St Louis, Missouri • Cleveland, Ohio

Conditions: Breast Implants
Interventions: Silicone gel-filled breast implants - Motiva Implants® Investigational breast implants; Device
Lead sponsor: Motiva USA LLC; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2033
U.S. locations: 27
States / cities: Beverly Hills, California • Santa Monica, California • Westlake Village, California + 20 more

Conditions: Refractory CLL, Refractory Lymphoma, Relapsed CLL
Interventions: BAFF CAR-T, Cyclophosphamide, Fludarabine, Obinutuzumab; Drug
Lead sponsor: Paolo Caimi, MD; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Other Cancer
Interventions: ruxolitinib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 7
States / cities: Duarte, California • Tampa, Florida • Boston, Massachusetts + 4 more

Conditions: Aortic Dissection Type B
Interventions: Relay Pro Stent-Graft; Device
Lead sponsor: Bolton Medical; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 21
States / cities: Los Angeles, California • Aurora, Colorado • Hartford, Connecticut + 17 more

Conditions: B Cell Precursor Type Acute Leukemia, Chronic Myeloid Leukemia, Leukemia, Myeloid, Chronic, Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia
Interventions: Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab; Drug
Lead sponsor: Ascentage Pharma Group Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 8
States / cities: Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 5 more

About this Cleveland Clinic institution page

What this page lists: ClinicalTrials.gov records that list Cleveland Clinic in Cleveland, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Cleveland Clinic

Filter and sort this campus

Stored official records

Trisol System EFS Study

Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection

Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring

Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy

Study of the Safety and Effectiveness of Motiva Implants®

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)

Study of the RelayPro Thoracic Stent-Graft in Subjects With an Acute, Complicated Type B Aortic Dissection

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

About this Cleveland Clinic institution page